Investors with an eye on the burgeoning field of cancer diagnostics may want to consider Personalis, Inc. (NASDAQ: PSNL), a significant player in the healthcare sector’s diagnostics and research industry. With an impressive market cap of $745.07 million, Personalis offers innovative genomic tests and services that have positioned it as a frontrunner in the fight against cancer.
**Current Market Position**
Currently trading at $8.39, Personalis has seen a slight dip of 0.06% in its latest trading session. However, its 52-week performance reveals a price range between $3.00 and $11.25, indicating both the volatility and potential of this stock. The company’s forward P/E ratio stands at -8.62, suggesting that while it is…
